Work

Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia

Year: 2025

Type: article

Abstract: Background: Real-world evidence for hypomethylating agent (HMA) + venetoclax 50 mg (VEN50) with voriconazole and posaconazole in acute myeloid leukemia (AML), is limited. Methods: = 95). Results: We report that treatment with HMA + VEN50 with either azole elicits a response rate similar to that described in the VIALE-A trial. Reducing the VEN dose to 50 mg with either strong CYP3A4 inhibitor did not compromise on the efficacy of the combination. Conclusion: HMA + VEN50 with either posaconazole or voriconazole yields comparable responses to higher doses of VEN reported previously. Clinical trial registration: The authors have confirmed clinical trial registration is not needed for this submission.

Source: eJHaem

DOI: 10.1002/jha2.70049